<p>AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma</p>
Yuxuan Zhu(Zhejiang University of Water Resource and Electric Power), Lei Zhong(Shanghai Jiao Tong University), Rongsheng Tong(University of Electronic Science and Technology of China), Xingmei Duan(Southwest Forestry University), Yuan Zhang(Jiangsu Cancer Hospital), Jianyou Shi(University of Electronic Science and Technology of China), Lan Bai(Shanghai Jiao Tong University), Ting Yuan(Goethe University Frankfurt)
Cited by 13
Related Papers
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.7k
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
|Signal Transduction and Targeted Therapy|2020|893